The NO/cGMP pathway inhibits Rap I activation in human platelets via cGMP-dependent protein kinase I

Thrombosis and Haemostasis

Volumn 93, Issue 2, 2005, Pages 319-325

  Danielewski, Oliver ^a   Schultess, Jan ^a   Smolenski, Albert ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

cGMP; Kinase; Nitric oxide; Platelet physiology; Rap I

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANYLATE CYCLASE; INTEGRIN; NITRIC OXIDE; NITRIC OXIDE DONOR; NUCLEOTIDE BINDING PROTEIN; RAP PROTEIN;

ARTICLE; BINDING SITE; CALCIUM SIGNALING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CALCIUM SIGNALING; CELL LINE; COLLAGEN; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; MEGAKARYOCYTES; NITRIC OXIDE; NITRIC OXIDE DONORS; RAP1 GTP-BINDING PROTEINS; TRANSFECTION;

EID: 13844276837     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-09-0582     Document Type: Article

References (51)

1. Pareti FI, Carrera D, Mannucci L, et al. Effect on platelet functions of derivatives of cyclic nucleotides. Thromb Haemost 1978; 39: 404-10.
2. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990; 87: 5193-7.
3. Wallerath T, Gath I, Aulitzky WE, et al. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost 1997; 77: 163-7.
4. Friebe A, Müllershausen F, Smolenski A, et al. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998; 54: 962-7.
5. Feil R, Lohmann SM, de Jonge H, et al. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003; 93: 907-16.
6. Münzel T, Feil R, Mülsch A, et al. Physiology and pathophysiology of vascular signaling controlled by guanosine 3′,5′-cyclic monophosphate-dependent protein kinase [corrected]. Circulation 2003; 108: 2172-83.
7. Eigenthaler M, Ullrich H, Geiger J, et al. Defective nitrovasodilator-stimulated protein phosphorylation and calcium regulation in cGMP-dependent protein kinase-deficient human platelets of chronic myelocytic leukemia. J Biol Chem 1993; 268: 13526-31.
8. Massberg S, Sausbier M, Klatt P, et al. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med 1999; 189: 1255-64.
9. Bos JL, de Bruyn K, Enserink J, et al. The role of Rap1 in integrin-mediated cell adhesion. Biochem Soc Trans 2003; 31: 83-6.
10. Hattori M, Minato N. Rap1 GTPase: functions, regulation, and malignancy J Biochem (Tokyo) 2003; 134: 479-84.
11. Kinbara K, Goldfinger LE, Hansen M, et al. Ras GTPases: integrins' friends or foes? Nat Rev Mol Cell Biol 2003; 4: 767-76.
12. Stork PJ. Does Rap1 deserve a bad Rap? Trends Biochem Sci 2003; 28: 267-75.
13. Siess W, Winegar DA, Lapetina EG. Rap1-B is phosphorylated by protein kinase A in intact human platelets. Biochem Biophys Res Commun 1990; 170: 944-50.
14. Klinz FJ, Seifert R, Schwaner I, et al. Generation of specific antibodies against the rap1A, rap1B and rap2 small GTP-binding proteins. Analysis of rap and ras proteins in membranes from mammalian cells. Eur J Biochem 1992; 207: 207-13.
15. Torti M, Lapetina EG. Structure and function of rap proteins in human platelets. Thromb Haemost 1994; 71: 533-43.
16. Bertoni A, Tadokoro S, Eto K, et al. Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem 2002; 277: 25715-21.
17. de Bruyn KM, Zwartkruis FJ, de Rooij J, et al. The small GTPase Rap1 is activated by turbulence and is involved in integrin [alpha] IIb[beta] 3-mediated cell adhesion in human megakaryocytes. J Biol Chem 2003; 278: 22412-7.
18. Crittenden JR, Bergmeier W, Zhang Y, et al. Cal-DAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10: 982-6.
19. Franke B, Akkerman JW, Bos JL. Rapid Ca2+-mediated activation of Rap1 in human platelets. Embo J 1997; 16: 252-9.
20. Franke B, van Triest M, de Bruijn KM, et al. Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol 2000; 20: 779-85.
21. Lova P, Paganini S, Sinigaglia E et al. A Gi-dependent pathway is required for activation of the small GTPase Rap1 B in human platelets. J Biol Chem 2002; 277: 12009-15.
22. Woulfe D, Jiang H, Mortensen R, et al. Activation of Rap1B by G(i) family members in platelets. J Biol Chem 2002; 277: 23382-90.
23. Larson MK, Chen H, Kahn ML, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003; 101: 1409-15.
24. Lova P, Paganini S, Hirsch E, et al. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J Biol Chem 2003; 278: 131-8.
25. Kawata M, Kikuchi A, Hoshijima M, et al. Phosphorylation of smg p21, a ras p21-like GTP-binding protein, by cyclic AMP-dependent protein kinase in a cell-free system and in response to prostaglandin E1 in intact human platelets. J Biol Chem 1989; 264: 15688-95.
26. Miura Y, Kaibuchi K, Itoh T, et al. Phosphorylation of smg p21B/rap1B p21 by cyclic GMP-dependent protein kinase. FEBS Lett 1992; 297: 171-4.
27. Grunberg B, Kruse HJ, Negrescu EV, et al. Platelet rap1B phosphorylation is a sensitive marker for the action of cyclic AMP- and cyclic GMP-increasing platelet inhibitors and vasodilators. J Cardiovasc Pharmacol 1995; 25: 545-51.
28. Smolenski A, Bachmann C, Reinhard K, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998; 273: 20029-35.
29. Smolenski A, Poller W, Walter U, et al. Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J Biol Chem 2000; 275: 25723-32.
30. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 113-22.
31. Moro MA, Russel RJ, Cellek S, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A 1996; 93: 1480-5.
32. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-61.
33. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
34. Baurand A, Raboisson P, Freund M, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 2001; 412: 213-21.
35. Freedman JE, Sauter R, Battinelli EM, et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 1999; 84: 1416-21.
36. Chiang TM, Woo-Rasberry V, Cole F. Role of platelet endothelial form of nitric oxide synthase in collagen-platelet interaction: regulation by phophorylation. Biochim Biophys Acta 2002; 1592: 169-74.
37. Fleming I, Schulz C, Fichtlscherer B, et al. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-71.
38. Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003; 112: 77-86.
39. Li Z, Ajdic J, Eigenthaler M, et al. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 2003; 101: 4423-9.
40. Gambaryan S, Geiger J, Schwarz UR, et al. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004; 103: 2593-600.
41. Marshall SJ, Senis YA, Auger JM, et al. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood 2004; 103: 2601-9.
42. Hardy AR, Jones ML, Mundell SJ, et al. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood 2004; 104: 1745-52.
43. Aktas B, Honig-Liedl P, Walter U, et al. Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase. Biochem Pharmacol 2002; 64: 433-9.
44. Siess W, Grunberg B. Phosphorylation of rap1B by protein kinase A is not involved in platelet inhibition by cyclic AMP. Cell Signal 1993; 5: 209-14.
45. Massberg S, Gruner S, Konrad I, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-42.
46. Aszodi A, Pfeifer A, Ahmad M, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo J 1999; 18: 37-48.
47. Hauser W, Knobeloch KP, Eigenthaler M, et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 1999; 96: 8120-5.
48. Lafuente EM, van Puijenbroek AA, Krause M, et al. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell 2004; 7: 585-95.
49. Müllershausen F, Friebe A, Feil R, et al. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 2003; 160: 719-27.
50. Butt E, Gambaryan S, Gottfert N, et al. Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem 2003; 278: 15601-7.
51. Butt E, Immler D, Meyer HE, et al. Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 2001; 276: 7108-13.